InnoCare Pharma’s Post

View organization page for InnoCare Pharma, graphic

2,615 followers

British Journal of Cancer recently published a paper entitled "Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents". The journal concluded that zurletrectinib is a novel, highly potent next-generation TRK inhibitor with stronger in vivo brain penetration and intracranial activity than other next-generation agents. Check out the full release: https://lnkd.in/etUEhqYJ Check out the full paper: https://lnkd.in/eWzJMD-u

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics